NR1H4 and metabolic dysfunction-associated steatohepatitis: Using the ligand of FXR named obeticholic acid (OCA) has been proven to improve insulin sensitivity in phase II and III trials in patients with nonalcoholic steatohepatitis (NASH) [7].